Alanko, J., Tanner, M., Vanninen, R., Auvinen, A., and Isola, J. 2021. Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis. Breast cancer research and treatment 187: 267–274.
Bagegni, N., Thomas, S., Liu, N., Luo, J., Hoog, J., Northfelt, D. W., Goetz, M. P., Forero, A., Bergqvist, M., Karen, J., and Neumüller, M. 2017. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast cancer research 19: 1-11.
Britt, K. L., Cuzick, J., and Phillips, K. A. 2020. Key steps for effective breast cancer prevention. Nature Reviews Cancer 20: 417-436.
Dastsooz, H., Cereda, M., Donna, D., and Oliviero, S. 2019. A Comprehensive Bioinformatics Analysis of UBE2C in Cancers. International journal of molecular sciences, , 20: 2228 .
Edachery, S., Patil, P., Mohan, R., Aradhya, B., Shetty, J., Kabekkodu, S. P., Santra, M. K., Gonchigar, S. J., and Shetty, P. 2022. Loss of miR-936 leads to acquisition of androgen-independent metastatic phenotype in prostate cancer. Scientific reports, 12: 17070 .
Fanelli, G. N., Scarpitta, R., Cinacchi, P., Fuochi, B., Szumera-Ciećkiewicz, A., De Ieso, K., Ferrari, P., Fontana, A., Miccoli, M., Naccarato, A. G., and Scatena, C. 2021. Immunohistochemistry for Thymidine Kinase-1 (TK1): A Potential Tool for the Prognostic Stratification of Breast Cancer Patients. . Journal of clinical medicine 10: 5416.
Filipów, S., and Łaczmański, Ł. 2019. Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response. Frontiers in genetics 10: 169.
Garcia-Martinez, L., Zhang, Y., Nakata, Y., Chan, H. L., and Morey, L. 2021. Epigenetic mechanisms in breast cancer therapy and resistance. Nature communications 12: 1786.
Grimaldi, A. M., Salvatore, M., and Incoronato, M. 2021. miRNA-based therapeutics in breast cancer: a systematic review. Frontiers in oncology 11: 668464.
Jeong, S. M., Bui, Q. T., Kwak, M., Lee, J. Y., and Lee, P. C. W. 2022. Targeting Cdc20 for cancer therapy. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 188824.
Jiang, Y., Liu, Y., Tan, X., Yu, S., and Luo, J. 2019. TPX2 as a Novel Prognostic Indicator and Promising Therapeutic Target in Triple-negative Breast Cancer. Clin Breast Cancer 19: 450-455. .
Kelly, J., Moyeed, R., Carroll, C., Albani, D., and Li, X. 2019. Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease. Molecular brain 12: 1-10.
Latha, N. R., Rajan, A., Nadhan, R., Achyutuni, S., Sengodan, S. K., Hemalatha, S. K., Varghese, G. R., Thankappan, R., Krishnan, N., Patra, D., and Warrier, A. 2020. Gene expression signatures: A tool for analysis of breast cancer prognosis and therapy. Critical Reviews in Oncology/Hematology 151: 102964.
Lin, X. J., Liu, H., Li, P., Wang, H. F., Yang, A. K., Di, J. M., Jiang, Q. W., Yang, Y., Huang, J. R., Yuan, M. L., and Xing, Z. H. 2020. miR-936 suppresses cell proliferation, invasion, and drug resistance of laryngeal squamous cell carcinoma and targets GPR78. Frontiers in oncology 10: 60.
Liu, S., Gong, Y., Xu, X. D., Shen, H., Gao, S., Bao, H. D., Guo, S. B., Yu, X. F., and Gong, J. 2021. MicroRNA‐936/ERBB4/Akt axis exhibits anticancer properties of gastric cancer through inhibition of cell proliferation, migration, and invasion. The Kaohsiung Journal of Medical Sciences 37: 111-120.
Loh, H. Y., Norman, B. P., Lai, K. S., Rahman, N. M. A. N. A., Alitheen, N. B. M., and Osman, M. A. 2019. The regulatory role of microRNAs in breast cancer. International journal of molecular sciences 20: 4940.
Lu, Y., Chen, X., Liu, F., Yu, H., Zhang, Y., Du, K., Nan, Y., and Huang, Q. 2022. Systematic pan cancer analysis identifies CDC45 as having an oncogenic role in human cancers. Oncology Reports 48: 1-16.
Matson, D. R., Denu, R. A., Zasadil, L. M., Burkard, M. E., Weaver, B. A., Flynn, C., and Stukenberg, P. T. 2021. High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability. BMC cancer 21: 1-11.
Matthews, H. K., Bertoli, C., and de Bruin, R. A. 2022. Cell cycle control in cancer. Nature Reviews Molecular Cell Biology 23: 74-88.
Parashar, D., Geethadevi, A., Aure, M. R., Mishra, J., George, J., Chen, C., Mishra, M. K., Tahiri, A., Zhao, W., Nair, B., and Lu, Y. 2019. miRNA551b-3p activates an oncostatin signaling module for the progression of triple-negative breast cancer. Cell reports 29: 4389-4406.
Won, K. A., and Spruck, C. 2020. Triple‑negative breast cancer therapy: Current and future perspectives. International journal of oncology 57: 1245-1261.
Xu, T., Dong, M., Li, H., Zhang, R., and Li, X. 2020. Elevated mRNA expression levels of DLGAP5 are associated with poor prognosis in breast cancer. Oncology letters 19: 4053–4065. .
Yin, L., Duan, J. J., Bian, X. W., and Yu, S. C. 2020. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research 22: 1-13.